Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

David R Snydman; Laura A McDermott; Nilda V Jacobus; Kathryn Kerstein; Trudy H Grossman; Joyce A Sutcliffe

doi:10.1128/AAC.02206-17

Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02206-17. doi: 10.1128/AAC.02206-17. Print 2018 May.

Authors

David R Snydman¹, Laura A McDermott², Nilda V Jacobus², Kathryn Kerstein³, Trudy H Grossman³, Joyce A Sutcliffe³

Affiliations

¹ Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA dsnydman@tuftsmedicalcenter.org.
² Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
³ Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA.

Abstract

The novel fluorocycline antibiotic eravacycline is in development for use in the treatment of serious infections caused by susceptible and multidrug-resistant (MDR) aerobic and anaerobic Gram-negative and Gram-positive pathogens. Eravacycline and 11 comparator antibiotics were tested against recent anaerobic clinical isolates, including MDR Bacteroides spp. and Clostridium difficile Eravacycline was potent in vitro against all the isolates tested, including strains with tetracycline-specific resistance determinants and MDR anaerobic pathogens resistant to carbapenems and/or β-lactam-β-lactamase inhibitor combinations.

Keywords: Bacteroides; anaerobes; antimicrobial resistance; eravacycline.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology*
Bacteria, Anaerobic / drug effects*
Drug Resistance, Bacterial
Microbial Sensitivity Tests
Tetracyclines / pharmacology*

Substances

Anti-Bacterial Agents
Tetracyclines
eravacycline